ForteBio, Inc. Announces Launch of Protein G Biosensor for Use on Company's Octet(R) Instruments
Published: Sep 03, 2010
MENLO PARK, Calif., Sept. 3 /PRNewswire/ -- ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Dip and Read Protein G biosensor for rapid detection and quantification of numerous types of mammalian immunoglobulin (IgG), an antibody molecule, from solution. Because it runs on the company's label-free Octet instrumentation platform, the new biosensor enables such measurements with unprecedented speed, ease of use and cost-efficiency. The company also announced that it has completed International Standards Organization (ISO) certification of its biosensor manufacturing facility.
"Protein G uniquely binds to many mammalian IgGs, such as murine, goat, bovine and other IgGs, making it an important tool in antibody discovery, cell line development and production monitoring," said Christopher Silva, ForteBio's vice president of marketing. "Traditional IgG quantification methods for numerous species and subtypes using Protein G, however, are complicated, labor-intensive and time-consuming. Now, with ForteBio's new Protein G biosensor, researchers can obtain highly specific binding information in real time, in a cost-effective and easy-to-use manner." Mr. Silva also noted that the company's Protein G biosensor can be regenerated and reused, for increased workflow flexibility and cost-efficiency.
The new biosensor comes with recombinant Protein G pre-immobilized on the surface and is ready to use on ForteBio's Octet instruments. ForteBio's Octet platform is based on the company's proprietary BioLayer Interferometry (BLI) technology, which uses optical biosensors to measure multiple interactions in parallel, without the use of detection agents. The Octet platform consists of 8- and 16-channel instruments that accommodate 96- and 384-well assay formats. All Octet biosensors are designed to simplify kinetic characterization and quantitation by eliminating throughput and time-to-result limitations of traditional SPR-based assays and ELISA. The Octet biosensors are disposable, configured in a standard microplate format and are coated with a proprietary biocompatible matrix that is uniform, non-denaturing and has minimal non-specific binding.
To date over 2.5 million biosensor assays have been run on Octet systems, a testament to the high reproducibility, accuracy and robustness of the platform.
The company also announced that its biosensor manufacturing facility is now ISO 9001:2008-certified, underscoring the quality of its products.
ABOUT FORTEBIO, INC.
ForteBio is a life science company that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio's analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com.
SOURCE ForteBio, Inc.